Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-0090
- Development stage
- Preclinical
- Lead developer
- Changtai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PC-0090 is a small molecule therapeutic candidate being developed by Changtai Pharmaceutical (also known as PharmaMax Corp) for the treatment of schizophrenia. It is formulated as an oral solution, which may offer advantages in terms of ease of administration and improved compliance for patients who have difficulty swallowing solid dosage forms. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed in the company's high-level pipeline, Changtai Pharmaceutical specializes in the development of improved formulations and drug delivery systems for established central nervous system (CNS) and respiratory therapies.
Beyond the preview
Go deeper on PC-0090.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC-0090.